Stopped: Study termination based on sponsor decision due to lack of tolerability observed with \[177Lu\]Lu-EVS459
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-EVS459 and the safety and imaging properties of \[68Ga\]Ga-EVS459 in patients aged ≥ 18 years with advanced high-grade serous ovarian cancer (OC) or locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (non-sq. NSCLC).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with dose limiting toxicities of [177Lu]Lu-EVS459
Timeframe: From start of study treatment until 6 weeks after
Incidence and severity of adverse events and serious adverse events of [177Lu]Lu- EVS459
Timeframe: From start of study treatment until completion of the 36 month follow up , assessed up to approximately 42 months
Dose modifications for [177Lu]Lu- EVS459
Timeframe: From start of study treatment until last dose of study treatment, assessed up to approximately 24 weeks
Dose intensity for [177Lu]Lu- EVS459
Timeframe: From start of study treatment until last dose of study treatment, assessed up to approximately 24 weeks